Lineage Cell Therapeutics (LCTX) Convertible Debt (2014 - 2017)

Lineage Cell Therapeutics' Convertible Debt history runs 4 years deep, the most recent figure standing at $1.9 million for Q4 2017.

• On a quarterly basis, Convertible Debt rose 80.72% year-over-year to $1.9 million in Q4 2017; TTM through Dec 2017 was $1.9 million, a 80.72% increase from a year earlier, with the FY2017 full-year figure at $1.9 million, up 80.72% from the prior year.
• Convertible Debt advanced to $1.9 million in Q4 2017 per LCTX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Convertible Debt topped out at $1.9 million in Q4 2017 and bottomed at $60000.0 in Q4 2014.
• The 4-year median for Convertible Debt is $617908.0 (2015), against an average of $741132.4.
• Across the five-year window, Convertible Debt soared 440.0% in 2015 and fell 26.33% in 2016, its largest moves.
• Year by year, Convertible Debt stood at $60000.0 in 2014, then surged by 440.0% to $324000.0 in 2015, then surged by 218.52% to $1.0 million in 2016, then soared by 80.72% to $1.9 million in 2017.
• Per Business Quant, the three latest LCTX Convertible Debt figures stand at $1.9 million (Q4 2017), $1.1 million (Q1 2017), and $1.0 million (Q4 2016).